VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 15, 2017, details the results of VistaGen Therapeutics, Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Nevada and headquartered in South San Francisco, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders approved four key proposals at the Annual Meeting:
- Election of Directors: All five nominees (Jon S. Saxe, Shawn K. Singh, H. Ralph Snodgrass, Brian J. Underdown, and Jerry B. Gin) were elected to the Board of Directors with support ranging from 95.75% to 99.52% of votes cast.
- Charter Amendment: Stockholders approved an amendment to the Restated and Amended Articles of Incorporation to increase the number of authorized common shares from 30.0 million to 100.0 million. This required and received the affirmative vote of a majority of outstanding shares (62.71% For).
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2016 Stock Incentive Plan to increase the number of authorized shares issuable from 3.0 million to 10.0 million. This received 85.98% of votes cast.
- Auditor Ratification: Stockholders ratified the appointment of OUM & Co, LLP as the independent public accounting firm for the fiscal year ending March 31, 2018, with 93.57% of votes cast in favor.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves as a record of the completed voting process and the subsequent filing of the Charter Amendment with the Nevada Secretary of State.
Key Facts for Investor Verification
- Verify the effective date of the Charter Amendment increasing authorized shares to 100.0 million.
- Confirm the updated share count available for issuance under the amended 2016 Stock Incentive Plan (10.0 million).
- Review the definitive proxy statement filed on August 4, 2017, for detailed background on the proposals.
- Note that the newly elected directors will serve until the 2018 annual meeting.